Comparison of antitumor activity of a humanized anti-CD40 antibody and a humanized anti-CD20 antibody against Ramos lymphoma transplanted in SCID mice.

![Graph showing tumor volume comparison between Control Ab, hu anti-CD40, and Rituxan. Start on d13 4mg/kg/3 times/wk (3 doses). Day 21 Post Treatment. Tumor Volume (mm^3).]
Comparison of antitumor activity of a murine anti-CD40 antibody (SGN-14) and a humanized anti-CD20 antibody against Ramos lymphoma transplanted in SCID mice.

- Control Ab
- SGN-14
- Rituxan

Days Post Treatment

Start on d13
4mg/kg/3 times/wk (9 doses)

Tumor Volume (mm-3)

1.2 x 10^4 1 x 10^4 8000 6000 4000 2000

0 0 0 0 0 0

FIG. 2
Antitumor activity of a humanized anti-CD20 antibody and **humanized anti-CD40 antibody** against IM9, (CD20+, CD40+Multiple myeloma) transplanted in SCID mice

**FIG. 3**

Survival (total # mice)

Days Post Tumor Implant

Start on d3
4mg/kg/3 times/wk (9 doses)
Combination of a humanized anti-CD20 antibody and a murine anti-CD40 antibody (SGN-14) for antitumor activity against H.S. Sultan, (CD20+, CD40+multiple myeloma) transplanted in SCID mice.

**FIG. 4**

Diagram showing survival (total # mice) over days post tumor implant. Key:
- Control Ab
- SGN-14
- Rituxan
- Rituxan/SGN-14

Start on d3, 2mg/kg 3 times/wk (9 doses)
Anti-tumor activity of a murine anti-CD40 antibody (SGN-14) and an anti-CD20 antibody (RITUXAN®, brand) on RITUXAN®, brand resistant Ramos Lymphoma transplanted in SCID mice

**FIG. 5**

Start on d13
4mg/kg/3 times/wk (9 doses)